Mavacamten: Practical Answers for the Clinician and New Questions From the MAVA-Long-Term Extension Study
- PMID: 38176783
- DOI: 10.1016/j.jchf.2023.08.034
Mavacamten: Practical Answers for the Clinician and New Questions From the MAVA-Long-Term Extension Study
Keywords: Mavacamten; efficacy; hypertrophic cardiomyopathy; myosin inhibitor; safety.
Conflict of interest statement
Funding Support and Author Disclosures Dr Ammirati has received a grant from the Italian Ministry of Health (GR-2019-12368506; principal investigator of the investigator-driven MYTHS [Myocarditis Therapy With Steroids]) and a grant from Italian Ministry of Health and NextGenerationEU (PNRR-MAD-2022-12376225); and is a consultant for Kiniksa and Cytokinetics. Dr Gallone has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. JACC Heart Fail. 2024. PMID: 38176782 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
